@conference{8a55976e48b244ff898dee63add79b8d,
title = "CTIM-03. PHASE II STUDY OF REGORAFENIB IN BEVACIZUMAB REFRACTORY RECURRENT GLIOBLASTOMA",
author = "Yasmeen Rauf and Cathy Schilero and David Peereboom and Manmeet Ahluwalia",
note = "AbstractBACKGROUND. Most patients with glioblastoma (GBM) receive bevacizumab as part of their treatment. There is no good therapeutic option after bevacizumab; Neuro-oncology ; Conference date: 09-11-2020",
year = "2020",
month = nov,
day = "9",
doi = "10.1093/NEUONC/NOAA215.137",
language = "American English",
}